News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
324,913 Results
Type
Article (19393)
Company Profile (124)
Press Release (305396)
Section
Business (105206)
Career Advice (857)
Deals (18514)
Drug Delivery (83)
Drug Development (50580)
Employer Resources (79)
FDA (7604)
Job Trends (7715)
News (185396)
Policy (17315)
Tag
Academia (730)
Africa (407)
Alliances (27686)
Alzheimer's disease (520)
Antibody-drug conjugate (ADC) (39)
Approvals (7565)
Arizona (45)
Artificial intelligence (52)
Asia (24256)
Australia (3111)
Bankruptcy (170)
Best Places to Work (5352)
Biosimilars (57)
Biotechnology (57)
C2C Services and Suppliers (13316)
California (829)
Canada (535)
Cancer (219)
Cardiovascular disease (34)
Career advice (694)
Cell therapy (39)
China (79)
Clinical research (41097)
Collaboration (78)
COVID-19 (1052)
Cystic fibrosis (41)
Data (136)
Diabetes (51)
Diagnostics (1695)
Drug pricing (73)
Earnings (37809)
Employer resources (71)
Europe (50336)
Events (46962)
Executive appointments (92)
FDA (7698)
Florida (107)
Funding (54)
Gene therapy (57)
GLP-1 (424)
Government (1771)
Healthcare (5887)
Hotbed/Location (219413)
Illinois (91)
Indiana (79)
Infectious disease (1071)
Inflammatory bowel disease (58)
Interviews (113)
IPO (7258)
IRA (31)
Job creations (2431)
Job search strategy (642)
Kansas (54)
Layoffs (241)
Legal (4068)
Lung cancer (56)
Manufacturing (64)
Maryland (128)
Massachusetts (717)
Medical device (1988)
Medtech (1991)
Mergers & acquisitions (11173)
Metabolic disorders (211)
Minnesota (61)
Neuroscience (609)
New Jersey (333)
New York (254)
NextGen Class of 2024 (2341)
Non-profit (904)
North Carolina (285)
Northern California (383)
Obesity (135)
Ohio (47)
Opinion (166)
Patents (53)
Pennsylvania (236)
People (32640)
Pharmaceutical (63)
Phase I (12765)
Phase II (17411)
Phase III (14033)
Pipeline (71)
Podcasts (48)
Policy (53)
Postmarket research (1609)
Preclinical (4482)
Rare diseases (84)
Real estate (3169)
Regulatory (11952)
Research institute (821)
Resumes & cover letters (138)
South America (601)
Southern California (344)
Startups (2009)
Texas (96)
The Weekly (31)
United States (3648)
Vaccines (169)
Washington State (96)
Weight loss (137)
Date
Today (35)
Last 7 days (325)
Last 30 days (1081)
Last 365 days (18691)
2024 (12925)
2023 (19715)
2022 (25933)
2021 (26698)
2020 (24911)
2019 (20112)
2018 (15642)
2017 (17301)
2016 (16241)
2015 (18839)
2014 (14881)
2013 (12601)
2012 (13533)
2011 (13906)
2010 (12822)
324,913 Results for "nls pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NLS Pharmaceutics Announces Registered Direct Offering
NLS Pharmaceutics Ltd. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,277,750 of its common shares at a purchase price of $0.24 per share in a registered direct offering.
June 28, 2024
·
6 min read
Drug Development
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson’s Disease Treatments
NLS Pharmaceutics Ltd. today announced preclinical results from multiple in vitro studies targeting alpha-synuclein specifically the A53T mutation, that demonstrate the compounds’ potential to advance the treatment of Parkinson’s Disease (PD).
June 27, 2024
·
6 min read
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced the publication of the latest patent application (PCT/WO2024115797) by Aexon Labs with the World Intellectual Property Organization (WIPO).
June 11, 2024
·
7 min read
Deals
Nasdaq Panel Grants NLS Pharmaceutics’ Request for Extension to Comply with Continued Listing Requirements
NLS Pharmaceutics Ltd. announced today that it received notice from the Nasdaq Hearings Panel of The Nasdaq Stock Market that it has granted the Company an extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market, as discussed more fully below.
June 25, 2024
·
4 min read
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
NLS Pharmaceutics Ltd. today announced that Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics will attend the BIO-EUROPE Springtime Partnering Event taking place March 18-20, 2024.
March 14, 2024
·
1 min read
Drug Development
NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model
NLS Pharmaceutics Ltd. today announced promising results from its preclinical study KO-874 at the American Society of Clinical Psychopharmacology (ASCP) in Miami.
May 28, 2024
·
6 min read
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
NLS Pharmaceutics Ltd. announced that on May 22, 2024, the Company received an additional staff determination letter from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it did not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing set forth in Listing Rule 5550, and that the additional delinquency may serve as a separate basis for the delisting of the Company’s securities from Nasdaq.
May 24, 2024
·
4 min read
Business
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS”), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today a groundbreaking exclusive worldwide license agreement (the “License Agreement”) with Aexon Labs, Inc., a U.S.-based biotech firm (“Aexon”).
March 20, 2024
·
9 min read
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
NLS Pharmaceutics Ltd. announced that it has been notified by the Listing Qualifications Department of the Nasdaq Stock Market LLC that the Company’s plan to regain compliance submitted on February 23, 2024 has been approved.
March 11, 2024
·
4 min read
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
NLS Pharmaceutics Ltd. announced the closing of its previously announced registered direct offering of 7,000,000 of its common shares at a purchase price of $0.25 per share.
March 22, 2024
·
5 min read
1 of 32,492
Next